BeOne Medicines (BEIGF) Change in Cash (2015 - 2026)

BeOne Medicines (BEIGF) has reported Change in Cash for 12 consecutive years, with $427.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Cash rose 67.22% year-over-year to $427.2 million in Q2 2026; TTM through Jun 2026 was $2.5 billion, a 1383.51% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 460.15% from the prior year.
• Change in Cash was $427.2 million for Q2 2026 at BeOne Medicines, up from $243.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $1.3 billion in Q3 2025 and troughed at -$378.5 million in Q1 2024.
• A 5-year average of $49.9 million and a median of -$51.6 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash plunged 1064.93% in 2023 and surged 1286.91% in 2025, its largest moves.
• Over 5 years, Change in Cash stood at -$325.5 million in 2022, then surged by 132.29% to $105.1 million in 2023, then sank by 171.06% to -$74.7 million in 2024, then jumped by 768.32% to $499.1 million in 2025, then retreated by 14.4% to $427.2 million in 2026.
• The last three Change in Cash figures came in at $427.2 million (Q2 2026), $243.8 million (Q1 2026), and $499.1 million (Q4 2025), per Business Quant data.